title: ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy.
abstract: Renin-angiotensin system reactivity and the constitutive capacity of the renal tubule to reabsorb sodium play a role in the individual response to diuretic therapy; therefore we evaluated the blood pressure (BP) response to hydrochlorothiazide in 87 never-treated individuals with mild essential hypertension, according to ACE gene I/D and alpha-adducin Gly460Trp polymorphism. These genotypes where chosen because previous data showed their interaction in determining the BP response to salt probably was the result of their involvement in the activation of the renin-angiotensin system (ACE) and in the constitutive capacity of the kidney to reabsorb sodium (alpha-adducin) (treatment for 2 months). BP was measured after 3 run-in visits and after the first and second months of treatment by means of a standardized procedure. Data were analyzed by ANOVA, t test, and multivariate ANOVA for repeated measures (covarying for gender, age, and body mass index). Although basal mean BP (MBP) was similar in the different ACE and alpha-adducin genotypes, patients carrying at least one I allele of ACE and one 460Trp allele of alpha-adducin had the largest MBP decrease with treatment (12.7+/-1.9 mm Hg), the effect of the combination of genotypes being additive but not epistatic. These patients had an odds ratio of 15.75 of being a responder to hydrochlorothiazide compared with patients with Gly460Gly+DD, with the least MBP decrease (3.4+/-1.7 mm Hg). Alpha-adducin and ACE I/D polymorphism may be useful to predict the interindividual degree of response to hydrochlorothiazide; the analysis of the combination of the 2 genotypes increases the accuracy of the prediction of response to the drug.
authors.affiliation: Department of Nephrology and Graduate School of Nephrology Universita' Vita e Salute, Milan, Italy. sciarronealibrandi.mariateresa@hsr.it
authors.forename: Maria Teresa
authors.initials: MT
authors.lastname: Sciarrone
authors.forename: Paola
authors.initials: P
authors.lastname: Stella
authors.forename: Cristina
authors.initials: C
authors.lastname: Barlassina
authors.forename: Paolo
authors.initials: P
authors.lastname: Manunta
authors.forename: Chiara
authors.initials: C
authors.lastname: Lanzani
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Bianchi
authors.forename: Daniele
authors.initials: D
authors.lastname: Cusi
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002148:Calmodulin-Binding Proteins / Q000235:genetics*; D004232:Diuretics; D005260:Female; D005819:Genetic Markers; D005838:Genotype; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use*; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D007703:Peptidyl-Dipeptidase A / Q000235:genetics*; D011110:Polymorphism, Genetic; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome; D000099291:Adducins
chemical_list: D000959:Antihypertensive Agents; D002148:Calmodulin-Binding Proteins; D004232:Diuretics; D005819:Genetic Markers; D006852:Hydrochlorothiazide; D007703:Peptidyl-Dipeptidase A; D049993:Sodium Chloride Symporter Inhibitors; D000099291:Adducins